Growth hormone research

CJC-1295 with DAC
research guide

CJC-1295 with DAC is a modified growth hormone releasing hormone analog attached to a drug affinity complex intended to extend its activity beyond the very short half-life of natural GHRH. In a published trial, healthy adults given a single subcutaneous dose showed dose-dependent increases in growth hormone lasting 6 days or more and in IGF-1 lasting 9 to 11 days, with IGF-1 remaining elevated for up to 28 days after multiple doses; the study itself ran for 28 and 49 days to capture these effects [1]. It has no FDA-approved indication and is not evaluated to the standard of an approved drug.

Human studiesEditorial review: September 13, 2026

Evidence depends on population and formulation. Literature summary, not clinical peer review.

Looking for the product? Reign listings and business disclosure ↓

Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.

01 · Start with identity

What is CJC-1295 with DAC?

CJC-1295 with DAC refers to the specific GHRH-analog-plus-affinity-complex molecule studied in the cited pharmacology trial, developed by a pharmaceutical sponsor for that research program. Reign Peptide's product is a separately manufactured research-chemical vial of the same class labeled for laboratory use, with no confirmed identity match, purity certification tie, or sponsor relationship to the studied compound.

Also searched as: DAC:GRF, drug affinity complex GHRH analog

02 · Read the evidence

What the studies reported

01

Duration of GH and IGF-1 elevation after a single dose

After a single subcutaneous injection, CJC-1295 with DAC produced dose-dependent increases in mean plasma growth hormone of 2- to 10-fold lasting 6 days or more, and increases in mean plasma IGF-1 of 1.5- to 3-fold lasting 9 to 11 days; the estimated half-life of the compound itself was 5.8 to 8.1 days. [1]

02

Effect of repeated dosing and overall study design

The trial used two randomized, placebo-controlled, double-blind ascending-dose designs, one running 28 days and one running 49 days, to allow both single-dose and multiple-dose assessment; after multiple doses, mean IGF-1 levels stayed above baseline for up to 28 days, and no serious adverse reactions were reported. [1]

03 · Numbers in context

What does dosing evidence actually support?

The evidence base is a controlled pharmacology trial in healthy adult volunteers (ages 21 to 61) using ascending subcutaneous doses under direct study supervision, designed to characterize how long GH and IGF-1 stayed elevated after single and multiple dosing rather than to define a maintenance regimen for general use [1]. Reported findings were dose-dependent (with the best tolerability at 30 or 60 micrograms per kilogram in the study), and describe hormone response duration measured in days after dosing, not the overall length of the study itself; the trial did not evaluate a self-directed repeated dosing schedule of the kind discussed outside clinical research.

A study dose is not a personal dose. Population, route, formulation and supervision are part of the result. Online community schedules are not treated here as established clinical protocols.

04 · Safety and limits

What not to overlook

  • CJC-1295 with DAC has no FDA-approved indication; the cited trial is a phase 1-type pharmacology study, not an approval trial.
  • Sustained elevation of growth hormone and IGF-1 carries theoretical long-term risks that the short trial duration could not assess.
  • Research-chemical vials sold under this name have no confirmed identity or purity link to the studied compound.
  • The study population was healthy adults under close monitoring using specific studied doses (30 or 60 mcg/kg reported as best tolerated), which differs from unsupervised use.

05 · Product distinctions

Names are not interchangeable

The studied compound was an investigational injectable formulation administered under a clinical pharmacology protocol by the trial sponsor. Reign Peptide sells CJC-1295 with DAC as a lyophilized powder vial for laboratory research reconstitution; this is a distinct, separately sourced product with no established bioequivalence to the trial material.

06 · Handling and storage

Follow validated product instructions

A single water volume, refrigerator temperature or expiry window cannot be assumed for every compound and formulation. Use the exact manufacturer documentation and a validated laboratory procedure. If stability, solvent compatibility or microbiological quality is not documented, those properties remain unverified.

Refrigeration, clear appearance and bacteriostatic water do not make an unverified research product suitable for injection. This guide does not provide a mixing or administration procedure.

The existing concentration calculator checks arithmetic only. It cannot choose a safe dose or establish compatibility, sterility or shelf life.

Reign Peptide · Business disclosure

Research product listings

Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.

Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.

Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.

Supplies and accessories

Compare the actual specifications

Jorge's supply directory includes syringes, alcohol pads, storage cases, travel refrigeration and electrolytes, with separate links for the two travel refrigeration options. Accessory availability is not a recommendation to administer a research compound.

Affiliate disclosure: As an Amazon Associate I earn from qualifying purchases.

Amazon affiliate link

Alcohol pads

MED PRIDE, 70% isopropyl, 200 count per listing. An alcohol pad does not establish sterility of a research product.

View on Amazon ↗

Amazon affiliate link

Peptide fridge case

Listing: 63 slots for 3mL bottles, bag only. An organizer is not active refrigeration or a validated storage system.

View on Amazon ↗

Amazon affiliate link

Peptide travel case

Medineed travel case with temperature display and two ice packs per listing. Check dimensions and transport requirements.

View on Amazon ↗

See all supplies and accessories →

Questions still worth asking

What remains unresolved?

  • What are the safety implications of sustained GH and IGF-1 elevation over periods longer than the 49 days studied?
  • How does the drug affinity complex modification affect immunogenicity or long-term receptor sensitivity with repeated dosing?

Check the source

References and evidence scope

  1. Human trial · 2006Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults ↗

These are the sources reviewed for this page, not an exhaustive systematic review. Related compound research is identified as such. Product links are not scientific references.

Keep reading

Related research